Claudiu T Supuran
Claudiu T Supuran
Kamal M Dawood
Kamal M Dawood
Introduction: Benzofuran is a fundamental unit in numerous bioactive heterocycles. They have attracted chemists and medical researchers due to their broad range of biological activity, where some of them possess unique anticancer, antituber...
Agents for the prevention and treatment of age-related macular degeneration and macular edema: a literature and patent review [0.03%]
黄斑变性和水肿的防治药物研究进展：综述与专利分析
Claudiu T Supuran
Claudiu T Supuran
Introduction: Macular degeneration (MD) and macular edema (ME) are ophthalmologic diseases affecting an increasing number of the aging population. Until recently, there were few therapeutic options for both conditions but the last two decad...
Chandra S Boosani,Palanikumar Gunasekar,Devendra K Agrawal
Chandra S Boosani
Introduction: A multitude of cellular and physiological functions have been attributed to the biological activity of PTEN (Phosphatase and tensin homolog) such as inhibiting angiogenesis, promoting apoptosis, preventing cell proliferation, ...
Diagnostic markers for glaucoma: a patent and literature review (2013-2019) [0.03%]
青光眼的诊断标志物专利和文献回顾(2013-2019)
Silvia Bua,Claudiu T Supuran
Silvia Bua
Introduction: Glaucoma, a leading cause of irreversible blindness worldwide, is commonly diagnosed solely in advanced stages of the disease when important and irreversible losses of visual field have already occurred. The identification of ...
Adrenergic agonists and antagonists as antiglaucoma agents: a literature and patent review (2013-2019) [0.03%]
肾上腺素受体激动剂和拮抗剂作为抗青光眼药物的研究进展（2013-2019）
Alessio Nocentini,Claudiu T Supuran
Alessio Nocentini
Introduction: Glaucoma is a neurodegenerative disease of the eye characterized by selective retinal ganglion cell loss that provokes progressive defects in the visual field. Elevated intraocular pressure (IOP) is an important contributor fo...
Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018) [0.03%]
前列腺受体激动剂作为抗青光眼药物（2013-2018年专利回顾）
Andrea Angeli,Claudiu T Supuran
Andrea Angeli
Introduction: Elevated intraocular pressure (IOP) is the most prevalent risk factor for glaucoma. Prostaglandin analogs are a first-line therapy for glaucoma due to their ability to reduce IOP, once-daily dosing, efficacy, and minimal side-...
Novel method of treating macular degeneration: a patent evaluation (WO2018/107005) [0.03%]
治疗年龄相关性黄斑变性的新方法及其专利分析(WO2018/107005)
Clemente Capasso,Jean-Yves Winum
Clemente Capasso
Introduction: Age-related macular degeneration (AMD) is the leading cause of central vision loss in developed countries. Effective therapy for AMD is currently limited to the treatment of the patient with intravitreal injections of anti-VEG...
Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595 [0.03%]
ROCK抑制剂治疗青光眼和高眼压症的药物组合物及专利评估
Alessandro Bonardi,Claudiu T Supuran
Alessandro Bonardi
Introduction: Glaucoma refers to a heterogeneous group of optic neuropathies characterized by an enhanced intraocular pressure (IOP). To date, there are six available different drug classes for the treatment of glaucoma and ocular hypertens...
Retinoic acid receptor-related orphan receptor gamma-t (RORγt) inhibitors in clinical development for the treatment of autoimmune diseases: a patent review (2016-present) [0.03%]
临床开发中的视黄酸受体相关孤儿受体伽马-t(RORγt)抑制剂治疗自身免疫性疾病的专利回顾(2016-至今)
Nannan Sun,Huimin Guo,Yonghui Wang
Nannan Sun
Introduction: RORγt is critical for the differentiation of Th17 cells and the production of IL-17. Inhibition of RORγt is considered as a promising strategy to treat Th17-mediated autoimmune diseases. Quite a number of RORγt inhibitors h...